Linked Life Data

18375822

Source:http://linkedlifedata.com/resource/pubmed/id/18375822

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18375822rdf:typepubmed:Citationlld:pubmed
pubmed-article:18375822lifeskim:mentionsumls-concept:C0026339lld:lifeskim
pubmed-article:18375822lifeskim:mentionsumls-concept:C0026336lld:lifeskim
pubmed-article:18375822lifeskim:mentionsumls-concept:C0334634lld:lifeskim
pubmed-article:18375822lifeskim:mentionsumls-concept:C0174680lld:lifeskim
pubmed-article:18375822lifeskim:mentionsumls-concept:C0521447lld:lifeskim
pubmed-article:18375822lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:18375822lifeskim:mentionsumls-concept:C0376515lld:lifeskim
pubmed-article:18375822lifeskim:mentionsumls-concept:C0079419lld:lifeskim
pubmed-article:18375822lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:18375822lifeskim:mentionsumls-concept:C1420433lld:lifeskim
pubmed-article:18375822lifeskim:mentionsumls-concept:C1424666lld:lifeskim
pubmed-article:18375822lifeskim:mentionsumls-concept:C1415887lld:lifeskim
pubmed-article:18375822lifeskim:mentionsumls-concept:C1419040lld:lifeskim
pubmed-article:18375822lifeskim:mentionsumls-concept:C0598086lld:lifeskim
pubmed-article:18375822lifeskim:mentionsumls-concept:C0598388lld:lifeskim
pubmed-article:18375822lifeskim:mentionsumls-concept:C0547047lld:lifeskim
pubmed-article:18375822pubmed:issue4lld:pubmed
pubmed-article:18375822pubmed:dateCreated2008-4-16lld:pubmed
pubmed-article:18375822pubmed:abstractTextMolecular mechanisms responsible for lymphoma resistance to apoptosis often involve the bcl-2 pathway. In this study, we investigated the cell signaling pathways activated in bcl-2-overexpressing human mantle cell lymphoma cell lines (JVM-2 and Z-138) that have been treated with oblimersen, a molecular gene silencing strategy that effectively suppresses bcl-2 in vitro and in vivo. Z-138 cells expressed higher levels of bcl-2 and were more sensitive to the effects of bcl-2 silencing, mediated by oblimersen or bcl-2 small interfering RNA, in vitro. Tumors derived following injection of Z-138 cells were sensitive to oblimersen as judged by decreases in tumor growth rate and decreases in cell proliferation (as measured by Ki-67). Immunohistochemistry and Western blot analysis of oblimersen-treated Z-138 tumors revealed a dose-dependent decrease in bcl-2 levels and an associated increase in the proapoptotic proteins caspase-3 and caspase-9. Silencing bcl-2 in Z-138 xenografts revealed an associated dose-dependent suppression of bax, a decrease in nuclear factor-kappaB and phospho-nuclear factor-kappaB, and transient loss of p53 levels. Coimmunoprecipitation studies suggest that the latter observation is mediated by an association between bcl-2 and phospho-mdm2. Bcl-2 silencing also led to p27 down-regulation and coimmunoprecipitation studies point to a role for bcl-2 in regulation of p27 localization/degradation. Bcl-2 silencing was also correlated with loss of cyclin D1a protein levels but not cyclin D1b levels. Coimmunoprecipitation studies indicate that bcl-2 may mediate its effects on cyclin D1a via interaction with p38 mitogen-activated protein kinase as well as a previously unreported interaction between bcl-2 and cyclin D1a.lld:pubmed
pubmed-article:18375822pubmed:languageenglld:pubmed
pubmed-article:18375822pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:citationSubsetIMlld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18375822pubmed:statusMEDLINElld:pubmed
pubmed-article:18375822pubmed:monthAprlld:pubmed
pubmed-article:18375822pubmed:issn1535-7163lld:pubmed
pubmed-article:18375822pubmed:authorpubmed-author:GascoyneRandy...lld:pubmed
pubmed-article:18375822pubmed:authorpubmed-author:KyleAlastair...lld:pubmed
pubmed-article:18375822pubmed:authorpubmed-author:KlasaRichard...lld:pubmed
pubmed-article:18375822pubmed:authorpubmed-author:ChikhGhaniaGlld:pubmed
pubmed-article:18375822pubmed:authorpubmed-author:BallyMarcelMlld:pubmed
pubmed-article:18375822pubmed:authorpubmed-author:MasinDanaDlld:pubmed
pubmed-article:18375822pubmed:authorpubmed-author:KapanenAnita...lld:pubmed
pubmed-article:18375822pubmed:authorpubmed-author:WilsonIan MIMlld:pubmed
pubmed-article:18375822pubmed:authorpubmed-author:TuckerCatheri...lld:pubmed
pubmed-article:18375822pubmed:authorpubmed-author:HoffmanBrad...lld:pubmed
pubmed-article:18375822pubmed:issnTypePrintlld:pubmed
pubmed-article:18375822pubmed:volume7lld:pubmed
pubmed-article:18375822pubmed:ownerNLMlld:pubmed
pubmed-article:18375822pubmed:authorsCompleteYlld:pubmed
pubmed-article:18375822pubmed:pagination749-58lld:pubmed
pubmed-article:18375822pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:meshHeadingpubmed-meshheading:18375822...lld:pubmed
pubmed-article:18375822pubmed:year2008lld:pubmed
pubmed-article:18375822pubmed:articleTitleSilencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels.lld:pubmed
pubmed-article:18375822pubmed:affiliationDepartment of Advanced Therapeutics, BC Cancer Research Center, Vancouver, British Columbia, Canada V5Z 1L3. ctucker@bccrc.calld:pubmed
pubmed-article:18375822pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18375822pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:596entrezgene:pubmedpubmed-article:18375822lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18375822lld:entrezgene
lhgdn:association:21781lhgdn:found_inpubmed-article:18375822lld:lhgdn